Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Loser - TheStreet

Arena Pharmaceuticals

(

ARNA

) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 2%. By the end of trading, Arena Pharmaceuticals fell 25 cents (-2.4%) to $9.98 on average volume. Throughout the day, 21.8 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 21.7 million shares. The stock ranged in price between $9.86-$10.57 after having opened the day at $10.45 as compared to the previous trading day's close of $10.23. Other company's within the Drugs industry that declined today were:

Anthera Pharmaceuticals

(

ANTH

), down 16.1%,

Aoxing Pharmaceutical Company

(

AXN

), down 11.5%,

OxiGene

(

OXGN

), down 11.1%, and

Supernus Pharmaceuticals

(

SUPN

), down 9.1%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.25 billion and is part of the

health care

sector. Shares are up 447.1% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the positive front,

Prima Biomed Ltd. ADR

(

PBMD

), up 43.4%,

Ampio Pharmaceuticals

(

AMPE

), up 28.9%,

K-V Pharmaceutical Company

(

KV.B

), up 21.7%, and

K-V Pharmaceutical Company

(

KV.A

), up 14.9%, were all gainers within the drugs industry with

Johnson & Johnson

(

JNJ

) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null